Attenuating influenza a virus infection by heparin binding EGF-like growth factor.
K M LaiBey Hing GohWai-Leng LeePublished in: Growth factors (Chur, Switzerland) (2021)
Cell entry of influenza A virus (IAV) was reported to be promoted by epidermal growth factor receptor (EGFR). On the other hand, binding of heparin-binding EGF-like growth factor (HB-EGF) to EGFR leads to internalisation and degradation of the receptors. This study aimed to testify whether or not HB-EGF-induced downregulation of EGFR could attenuate IAV cell entry and subsequently diminish the infection. Immunoblotting and plaque assay revealed that HB-EGF-induced degradation of EGFR led to reduction of viral matrix 1 protein level and suppressed virion production. In addition, immunoblotting and imaging flow cytometric analysis demonstrated that IAV-induced phosphorylation of STAT1 and its localisation to nucleus in the early stage of infection were inhibited by HB-EGF treatment. This suggested the potential of HB-EGF in modulating uncontrolled and exaggerated inflammatory response caused by IAV infection. Together these findings attest the potential of HB-EGF mediated endocytosis and degradation of EGFR as a novel anti-IAV strategy.
Keyphrases
- growth factor
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- early stage
- inflammatory response
- high glucose
- diabetic rats
- drug induced
- squamous cell carcinoma
- signaling pathway
- cell proliferation
- cell therapy
- dna binding
- stem cells
- venous thromboembolism
- oxidative stress
- lipopolysaccharide induced
- transcription factor
- mesenchymal stem cells
- small molecule
- climate change
- risk assessment
- fluorescence imaging
- protein protein